Literature DB >> 21723940

Nurr1 is not essential for the development of prepulse inhibition deficits induced by prenatal immune activation.

Stéphanie Vuillermot1, Joram Feldon, Urs Meyer.   

Abstract

Inflammation-induced disruption of fetal neurodevelopmental processes has been linked to the precipitation of long-lasting behavioral abnormalities and associated neuropathology. Recent longitudinal investigations in prenatal immune activation models have revealed developmental correspondences between the ontogeny of specific dopaminergic neuropathology and the postnatal onset of distinct forms of dopamine-dependent functional abnormalities implicated in schizophrenia. Two examples of such developmental correspondences are increased expression of the orphan nuclear receptor Nurr1 (NR4A2) in ventral midbrain areas and disruption of prepulse inhibition of the acoustic startle reflex, with both the neuroanatomical and behavioral effects emerging only in adult but not pre-pubertal subjects exposed to prenatal maternal inflammation. In the present study, we tested the hypothesis that Nurr1 may be a critical molecular mediator of prepulse inhibition deficits induced by prenatal immune activation. To this end, we compared the effects of prenatal immune challenge on adult PPI in wild-type (wt) mice and mice with a heterozygous constitutive deletion of Nurr1 (Nurr1+/-) using a well established mouse model of maternal immune activation by exposure to the viral mimetic poly(I:C) (=polyriboinosinic-polyribocytidilic acid). We found that prenatal poly(I:C) treatment on gestation day 9 was similarly effective in disrupting prepulse inhibition in adult wt and Nurr1+/- mice. Prenatal poly(I:C) treatment also generally increased midbrain Nurr1-positive cells and counteracted the genetically driven Nurr1 deficit in the substantia nigra. Our data thus suggest that at least under the present experimental conditions, Nurr1 is not essential for the development of prepulse inhibition deficits induced by prenatal immune activation.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21723940     DOI: 10.1016/j.bbi.2011.06.012

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  7 in total

Review 1.  Animal models of gene-environment interaction in schizophrenia: A dimensional perspective.

Authors:  Yavuz Ayhan; Ross McFarland; Mikhail V Pletnikov
Journal:  Prog Neurobiol       Date:  2015-10-25       Impact factor: 11.685

Review 2.  Evidence for a dysregulated immune system in the etiology of psychiatric disorders.

Authors:  Sinead M Gibney; Hemmo A Drexhage
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-05       Impact factor: 4.147

Review 3.  Brain changes in a maternal immune activation model of neurodevelopmental brain disorders.

Authors:  Lara Bergdolt; Anna Dunaevsky
Journal:  Prog Neurobiol       Date:  2018-12-24       Impact factor: 11.685

4.  Chronic Toxoplasma gondii in Nurr1-null heterozygous mice exacerbates elevated open field activity.

Authors:  Jeffrey B Eells; Andrea Varela-Stokes; Shirley X Guo-Ross; Evangel Kummari; Holly M Smith; Erin Cox; David S Lindsay
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

5.  Targeting Glia with N-Acetylcysteine Modulates Brain Glutamate and Behaviors Relevant to Neurodevelopmental Disorders in C57BL/6J Mice.

Authors:  Alice M S Durieux; Cathy Fernandes; Declan Murphy; Marie Anais Labouesse; Sandra Giovanoli; Urs Meyer; Qi Li; Po-Wah So; Grainne McAlonan
Journal:  Front Behav Neurosci       Date:  2015-12-14       Impact factor: 3.558

6.  Maternal Vitamin D Prevents Abnormal Dopaminergic Development and Function in a Mouse Model of Prenatal Immune Activation.

Authors:  Wei Luan; Luke Alexander Hammond; Stephanie Vuillermot; Urs Meyer; Darryl Walter Eyles
Journal:  Sci Rep       Date:  2018-06-27       Impact factor: 4.379

7.  Transgenerational modification of dopaminergic dysfunctions induced by maternal immune activation.

Authors:  Ulrike Weber-Stadlbauer; Juliet Richetto; Ramona A J Zwamborn; Roderick C Slieker; Urs Meyer
Journal:  Neuropsychopharmacology       Date:  2020-09-12       Impact factor: 7.853

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.